Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.44 Analyst target: $4.50 Upside: 212.50%
PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. The company is headquartered in Florham Park, New Jersey.
See the full interactive analysis & chart →Informational only — not investment advice.